Pfizer

• 10-QQ2 FY2026Impairment / charge

  Filed Aug 4

  Sigvotatug vedotin’s Phase 3 setback triggered an impairment and GAAP loss; falling COVID-19 sales offset Eliquis and Padcev gains.

  • Revenue$15.0BYoY +2.6%
  • Net income−$248.0Mvs $2.9B year ago

• 8-KEarningsGuidance reaffirmedImpairment / charge

  Filed Aug 4

  Non-COVID strength lifts revenue outlook despite weaker COVID-19 sales; sigvotatug vedotin and Oxbryta impairments drive GAAP loss.

• 8-KGuidance reaffirmed

  Filed Jun 18

  CFO transition announced; all FY2026 guidance reaffirmed.

• 8-KCEO/CFO change

  Filed Jun 18

  Dave Denton leaves for a consumer-goods opportunity; Cecile Guegan becomes interim CFO as Pfizer searches for a successor.

• 10-QQ1 FY2026Restructuring

  Filed May 5

  Padcev, Nurtec and Lorbrena gained as Comirnaty and Paxlovid fell; FX drove most reported growth while costs and taxes weighed on earnings.

  • Revenue$14.5BYoY +5.4%
  • Net income$2.7BYoY −9.4%

• 8-KEarningsGuidance reaffirmedLegal / investigation

  Filed May 5

  Launched and acquired products drive growth despite steep Comirnaty and Paxlovid declines.

• 8-KShareholder voteExecutive pay

  Filed Apr 27

  Shareholders approved the amended 2019 Stock Plan and rejected the independent chair proposal.

• 10-KFY2025Impairment / charge

  Filed Feb 26

  Paxlovid and Comirnaty declines masked non-COVID growth; the Metsera deal targets obesity as patent losses loom.

  • Revenue$62.6BYoY −1.6%
  • Net income$7.8BYoY −3.2%

• 8-KEarningsGuidance reaffirmedImpairment / charge

  Filed Feb 3

  Lower Comirnaty and Paxlovid sales outweighed growth elsewhere; FY2026 guidance reaffirmed despite pricing, tariff and exclusivity headwinds.

Coverage: 10-K filings filed since Feb 26, 2026; 10-Q since May 5, 2026; 8-K since Feb 3, 2026.

Request longer coverage

Company data: Wikidata Q206921